Latest Administration News

Macarthur Minerals has successfully raised A$1.25 million through an oversubscribed placement, positioning the company to advance exploration and maintain tenements at its Lake Giles Iron Project.

Cleo Diagnostics has completed blood sample collection for its pivotal U.S. clinical trial, advancing its Pre-Surgical Ovarian Cancer Test closer to FDA submission.

Nexsen Limited's subsidiary has won a HK$6 million grant to accelerate clinical validation and manufacturing of its rapid Group B Streptococcus diagnostic in Hong Kong, positioning the city as a key Asia-Pacific hub.

Temas Resources Corp has opted to reduce its financial reporting frequency, moving from quarterly to semi-annual reports under a Canadian Securities Exchange pilot program. This change aligns with its status as a venture issuer and reflects its ongoing focus on proprietary processing technology and mineral projects.

Genetic Technologies Limited remains under voluntary administration with minimal cash outflows and $0.276 million in cash as it navigates its Deed of Company Arrangement.

Genetic Technologies Limited remains under voluntary administration while progressing a Deed of Company Arrangement and has completed the sale of its geneType business, ending the quarter with $270,000 in cash.

Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for a suite of Australian domiciled iShares ETFs, outlining key dates and participation details for investors.

Greenvale Energy has promoted Alex Cheeseman from CEO to Managing Director as the company prepares for a pivotal 2026 field season across its uranium projects in the Northern Territory and Queensland.